GlassScriptPhysician profile
Aline Bayard
NPI 1972961068
$682.54
in general payments reported to CMS, 2019-2025
15 companies · $200 in 2025
The $200 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $186 · 2023: $17.42 · 2024: $278 · 2025: $200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $496.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $496.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $152.54 | 2025 | |
| Alkermes, INC. | $133.36 | 2022-2024 | Vivitrol |
| Abbvie INC. | $106.85 | 2022 | |
| Daiichi Sankyo INC. | $46.29 | 2024 | Injectafer |
| Shield Therapeutics INC | $38.83 | 2024 | |
| Gilead Sciences, INC. | $30.87 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $28.96 | 2024 | Lokelma, Farxiga |
| Ardelyx, INC. | $22.61 | 2024 | Ibsrela |
| Recordati_rare_diseases_inc. | $21.83 | 2024 | Signifor Lar, Isturisa |
| Novartis Pharmaceuticals Corporation | $17.42 | 2023 | |
| Merck Sharp & Dohme LLC | $17.18 | 2024 | Capvaxive, Gardasil, Gardasil 9 |
| Azurity Pharmaceuticals, INC. | $16.99 | 2025 | Azmiro |
| Pfizer INC. | $16.95 | 2024 | |
| Glaxosmithkline, LLC. | $16.06 | 2024 | Trelegy Ellipta |
| Exact Sciences Corporation | $15.80 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aline Bayard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.